Source comparison
10. MT-II vs afamelanotide (Scenesse)
Afamelanotide (the pharmaceutical name for Melanotan-1, MT-I) is the linear α-MSH analogue also developed from the University of Arizona programme. Differences: Structure: afamelanotide is linear (not cyclic); MT-II is cyclic Half-life: afamelanotide as a slow
This comparison does not assign a generated winner or score.
- Afamelanotide (the pharmaceutical name for Melanotan-1, MT-I) is the linear α-MSH analogue also developed from the University of Arizona programme. Differences:
- Structure: afamelanotide is linear (not cyclic); MT-II is cyclic
- Half-life: afamelanotide as a slow-release implant has effective tissue presence of ~60 days; MT-II is a short-acting injectable
- Approval: afamelanotide approved by EMA (2014) and FDA (2019) for erythropoietic protoporphyria (EPP) under the brand name Scenesse; MT-II not approved
- Research overlap: both are melanocortin agonists with MC1R-mediated melanogenic effects; afamelanotide is increasingly the preferred research tool where a regulated, named, clinically-studied comparator is required
- For UK research protocols requiring a regulated comparator or comparison to clinical EPP pharmacology, afamelanotide (Clinuvel-supplied implant, or research-grade peptide equivalent) is preferable. For in vitro and early-preclinical MC1R pharmacology, MT-II remains the most widely-cited research tool.